TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CORE-trial: a Pragmatic Randomized Controlled Trial in Primary Care Investigating Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme Offered Population-wide to 30-49 Years
Brief Summary: Check your health is a prevention intervention designed to create awareness and action on health condition with focus at physical activity at a population-level to 30-49 years of age. It consists of a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up; stratified after risk-profile. The CORE trial (Check your health) aim to investigate effectiveness on health and social outcomes of the preventive health check and to establish the cost-effectiveness according to life years gained; direct costs and total health costs. A pragmatic cluster randomised controlled trial has been established to meet the aims and in total 10.600 individuals from 35 practices have been randomized in to two groups that will be invited in 2013-14 and 2017-18 respectively. The group offered the preventive health check in 2013-14 will constitute the intervention group and the group examined in 2017 - 18 the control group. A follow up of the intervention group in 2017 - 18 will provide data for the intention to treat analysis revealing the effect. Outcome measures are level of physical activity, risk of getting cardiovascular disease, sick leave and labor market attachment.


Options:
A: Arm Label: Health check; Type: EXPERIMENTAL; Interventions: Other: Health check | Arm Label: No invitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Health check; Assigned to Arm(s): Health check
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
C: Arm Label: Updated CHD risk profiles; Type: EXPERIMENTAL; Interventions: Behavioral: Updated CHD risk profiles | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Guidelines | Intervention Type: BEHAVIORAL; Name: Updated CHD risk profiles; Assigned to Arm(s): Updated CHD risk profiles | Intervention Type: BEHAVIORAL; Name: Guidelines; Assigned to Arm(s): Guidelines
D: Arm Label: Direct-to-patient tailored cardiovascular risk message system; Type: EXPERIMENTAL; Interventions: Behavioral: Direct-to-patient tailored cardiovascular risk message system | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Direct-to-patient tailored cardiovascular risk message system; Assigned to Arm(s): Direct-to-patient tailored cardiovascular risk message system

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
Brief Summary: Guillian-Barre Syndrome (GBS) is the most frequent cause of acute neuromuscular weakness in the Western World and can occur at any age. GBS is a rpadily progressive 'inflammatory' disorder of the perihperal nerves often leading to sever paresis of the limbs. Most GBS patients also have sensory disturbances (tingling or dull feeling) and pain. Some patients also have double vision or problems with swallowing. GBS mau also involve the respiratory muscles, leading to insufficient ventilation and admission to an intensive care unit. GBS pateints have a vairable prognosis; 20-30% require mechnical ventilation for a period ranging from weeks to months, 20% are unable to walk after 6 months nad 3-5% dies. Progression of weakness in GBS is usually rapid and reaches its peak within 4 weeks in the majority of patients, but many develop their maximum deficit within 2 weeks. Thereafter, the patients have a variable prognosis.

GBS is a treatable disorder. Intravenous immunoglobulin (IVIg) 2g/kg administered in 5 days was shown to be effective when administered within the first two weeks after onset of symptoms, and is considered the treatment of choice by most experts in the field. Although the standard treatment for GBS is a single course of IVIg (2g/kg administered in 5 days), many patients fails to recover abd remain with substantial disability. Patients with GBS and especially those with a poor prognosis potentially may benefit from more powerful abd when possible a more mechanistically rational therapy.

Recent experimental evidence suggests that complement activation palys a crucial role in the development of neuromuscular weakness in GBS making complement inhibitors and regulators attracive therapeutic targets. Our hypothesis is that Eculizumab, with its function as a complement inhibitor, will be very effective in preventing progression of weakness in patients with GBS.


Options:
A: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab
B: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Novel Game Rehabilitation System (E-glove System) on Upper Extremity Function of Patients With Stroke :Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether novel upper extremity rehabilitation system for patients with stroke(e-glove system) are effective in the rehabilitation compared to conventional occupational therapy


Options:
A: Arm Label: E-glove system; Type: EXPERIMENTAL; Interventions: Device: E-glove system | Arm Label: Conventional occupational therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional occupational therapy | Intervention Type: DEVICE; Name: E-glove system; Assigned to Arm(s): E-glove system | Intervention Type: PROCEDURE; Name: Conventional occupational therapy; Assigned to Arm(s): Conventional occupational therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: robot therapy (ARMin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional therapy | Intervention Type: DEVICE; Name: robot therapy (ARMin); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional therapy; Assigned to Arm(s): 2
C: Arm Label: MusicGlove Group; Type: EXPERIMENTAL; Interventions: Device: MusicGlove | Arm Label: Control Group for Music Glove; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional hand exercise | Arm Label: Resonating Arm Exerciser (RAE); Type: EXPERIMENTAL; Interventions: Device: Resonating Arm Exerciser | Arm Label: Control Group for RAE; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Arm Exercise | Intervention Type: OTHER; Name: Conventional hand exercise; Assigned to Arm(s): Control Group for Music Glove | Intervention Type: DEVICE; Name: MusicGlove; Assigned to Arm(s): MusicGlove Group | Intervention Type: OTHER; Name: Conventional Arm Exercise; Assigned to Arm(s): Control Group for RAE | Intervention Type: DEVICE; Name: Resonating Arm Exerciser; Assigned to Arm(s): Resonating Arm Exerciser (RAE)
D: Arm Label: Virtual Reality Therapy; Type: EXPERIMENTAL; Interventions: Other: Virtual Reality | Arm Label: Traditional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Therapy | Intervention Type: OTHER; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality Therapy | Intervention Type: OTHER; Name: Traditional Therapy; Assigned to Arm(s): Traditional Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension
Brief Summary: To demonstrate that non-invasive renal denervation is safe and shows a net difference in blood pressure reduction when compared to sham in subjects with uncontrolled hypertension.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal denervation with a catheter-based procedure (Symplicity® Catheter System) | Arm Label: Maintenance of Medications; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Renal denervation with a catheter-based procedure (Symplicity® Catheter System); Assigned to Arm(s): Renal Denervation
B: Arm Label: Control group; Type: OTHER; Interventions: Procedure: Renal denervation | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Renal denervation | Intervention Type: PROCEDURE; Name: Renal denervation; Assigned to Arm(s): Control group, Intervention group
C: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation
D: Arm Label: Investigational Therapy (Surround Sound); Type: EXPERIMENTAL; Interventions: Device: Investigational Therapy (Surround Sound) | Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Device: Sham Control | Intervention Type: DEVICE; Name: Investigational Therapy (Surround Sound); Assigned to Arm(s): Investigational Therapy (Surround Sound) | Intervention Type: DEVICE; Name: Sham Control; Assigned to Arm(s): Sham Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Point-of-care Testing (POCT) and Assistance From Comprehensive Medication Management (CMM) Pharmacists Improve Early Detection and Management of Metabolic Syndrome in Patients Treated With Antipsychotic Medications?
Brief Summary: The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome. Subjects were also randomized to either an Extended Treatment Group (ETG) defined by receiving comprehensive medication management (CMM) pharmacist interventions or a Usual Treatment Group (UTG) receiving no CMM interventions. All subjects were recruited from three community mental health clinic settings in Minnesota.


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
C: Arm Label: ISTOP-ADE; Type: EXPERIMENTAL; Interventions: Other: ISTOP-ADE | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ISTOP-ADE; Assigned to Arm(s): ISTOP-ADE
D: Arm Label: Extended Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference, Behavioral: Comprehensive Medication Management | Arm Label: Usual Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference | Intervention Type: DEVICE; Name: Glucose and lipids; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Glycosylated Hemoglobin A1c; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Blood Pressure and Heart Rate; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Body mass index; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Waist and Hip circumference; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: BEHAVIORAL; Name: Comprehensive Medication Management; Assigned to Arm(s): Extended Treatment Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Three Therapeutic Strategies on the Restriction of the Participation of Patients With a Chronic Back Pain : Multidisciplinary is it the Key Component ?
Brief Summary: Effect of three therapeutics strategies on the restriction of the participation of patients with a chronic back pain : multidisciplinary is it the key component ?


Options:
A: Arm Label: Tailored Physical Activity; Type: EXPERIMENTAL; Interventions: Other: Tailored Physical Activity | Arm Label: Reference group; Type: OTHER; Interventions: Behavioral: Health Counselling | Intervention Type: OTHER; Name: Tailored Physical Activity; Assigned to Arm(s): Tailored Physical Activity | Intervention Type: BEHAVIORAL; Name: Health Counselling; Assigned to Arm(s): Reference group
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary intervention | Arm Label: Controll group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group, Brief Intervention | Intervention Type: BEHAVIORAL; Name: Interdisciplinary intervention; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control Group, Brief Intervention; Assigned to Arm(s): Controll group
C: Arm Label: PLURIHOC; Type: ACTIVE_COMPARATOR; Interventions: Other: functionnal reeducation | Arm Label: KIPLURI; Type: ACTIVE_COMPARATOR; Interventions: Other: functionnal reeducation | Arm Label: KIMONO; Type: ACTIVE_COMPARATOR; Interventions: Other: functionnal reeducation | Intervention Type: OTHER; Name: functionnal reeducation; Assigned to Arm(s): KIMONO, KIPLURI, PLURIHOC
D: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors: a Randomized Pilot Study
Brief Summary: The purpose of this study is to test the feasibility of two 6-month behavioral interventions for weight gain prevention (self-regulation plus activity monitoring or self-regulation) among African American breast cancer survivors along with a delayed control group. Participants will be 45 African American post-treatment breast cancer survivors. Intervention content will be delivered online with one face-to-face individual meeting. Weight, clinical and psychosocial measures will be assessed at baseline, 3 and 6 months. It is hypothesized that it is feasible to deliver the two weight gain prevention interventions among African American breast cancer survivors, and participants in the two intervention groups will have a lower magnitude of weight gain at 6-month follow-up relative to those in the delayed control group.


Options:
A: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Self-regulation plus activity monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Self-regulation plus activity monitoring | Arm Label: Self-regulation; Type: EXPERIMENTAL; Interventions: Behavioral: Self-regulation | Arm Label: Delayed intervention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-regulation plus activity monitoring; Assigned to Arm(s): Self-regulation plus activity monitoring | Intervention Type: BEHAVIORAL; Name: Self-regulation; Assigned to Arm(s): Self-regulation
C: Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)
Brief Summary: This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.


Options:
A: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): insulin detemir
B: Arm Label: IDeg OD ± OADs followed by IGlar OD ± OADs; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin glargine | Arm Label: IGlar OD ± OADs followed by IDeg OD ± OADs; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin degludec, Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD ± OADs followed by IGlar OD ± OADs, IGlar OD ± OADs followed by IDeg OD ± OADs | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IDeg OD ± OADs followed by IGlar OD ± OADs, IGlar OD ± OADs followed by IDeg OD ± OADs
C: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: NPH insulin; Type: EXPERIMENTAL; Interventions: Drug: insulin NPH, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): NPH insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): NPH insulin, insulin detemir
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: human insulin /insulin isophane | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: insulin levemir / aspart | Intervention Type: DRUG; Name: insulin levemir / aspart; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: human insulin /insulin isophane; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Brief Summary: Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019 cells) in non-Hodgkins Lymphoma (NHL) patients. The duration of active protocol intervention is approximately 24 months from screening visit. The protocol will require approximately 48 months to complete.


Options:
A: Arm Label: Treatment (T cell therapy); Type: EXPERIMENTAL; Interventions: Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes | Intervention Type: BIOLOGICAL; Name: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes; Assigned to Arm(s): Treatment (T cell therapy)
B: Arm Label: 19(T2)28z1xx CAR T cells; Type: EXPERIMENTAL; Interventions: Drug: 19(T2)28z1xx CAR T cells | Intervention Type: DRUG; Name: 19(T2)28z1xx CAR T cells; Assigned to Arm(s): 19(T2)28z1xx CAR T cells
C: Arm Label: CD30 positive NHL subtypes; Type: EXPERIMENTAL; Interventions: Drug: CD30.CAR-T | Intervention Type: DRUG; Name: CD30.CAR-T; Assigned to Arm(s): CD30 positive NHL subtypes
D: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Biological: CART-19 | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Biological: CART-19 | Arm Label: Cohort C; Type: EXPERIMENTAL; Interventions: Biological: CART-19 | Intervention Type: BIOLOGICAL; Name: CART-19; Assigned to Arm(s): Cohort A, Cohort B, Cohort C

Answer: D